Next Article in Journal
Serum Cystatin C as a Biomarker in Diffuse Large B-Cell Lymphoma
Next Article in Special Issue
Six-Month Chronic Toxicity Study of Tamarind Pulp (Tamarindus indica L.) Water Extract
Previous Article in Journal / Special Issue
Antimutagenic Activity of Ethanol Extract of Rhaphidophora pinnata (L.f) Schott Leaves on Mice
Article Menu

Export Article

Open AccessArticle
Sci. Pharm. 2017, 85(1), 8; doi:10.3390/scipharm85010008

Anticancer Dose Adjustment for Patients with Renal and Hepatic Dysfunction: From Scientific Evidence to Clinical Application

1
Institute of Pharmacy, Clinical Pharmacy, University of Bonn, D-53121 Bonn, Germany
2
School of Pharmacy, Institut Teknologi Bandung (ITB), Bandung 40132, Indonesia
3
Med. Klinik III und Poliklinik, Center for Integrated Oncology (CIO), University of Bonn, D-53127 Bonn, Germany
*
Author to whom correspondence should be addressed.
Academic Editor: Gernot Eller
Received: 22 December 2016 / Revised: 4 February 2017 / Accepted: 20 February 2017 / Published: 27 February 2017
View Full-Text   |   Download PDF [1629 KB, uploaded 27 February 2017]   |  

Abstract

Most anticancer agents exhibit a narrow therapeutic index, i.e., a small change in plasma concentrations can lead to a less efficacious treatment or an unacceptable degree of toxicity. This study aimed at providing health professionals with a feasible and time-saving tool to adapt the dose of anticancer agents for patients with renal or hepatic dysfunction. A guideline for anticancer agents was developed based on a literature search. An algorithm was generated to enhance the efficiency of the dose adaptation process. Finally, the dosing guideline was converted into an easy-to-use ExcelTM tool. The concept was applied to a total of 105 adult patients at the Centre for Integrated Oncology, Bonn, Germany. In total, 392 recommendations for dose adaptation were made and 320 (81.6%) recommendations were responded to by the oncologists. 98.4% of the recommendations were accepted. The algorithm simplifies the decision and screening process for high-risk patients. Moreover, it provides the possibility to quickly decide which laboratory tests are required and whether a dose adjustment for a particular anticancer drug is needed. The ExcelTM tool provides a recommended individual dose for patients with renal or hepatic dysfunction. The effectiveness of this strategy to reduce toxicity should be investigated in further studies before being adopted for routine use. View Full-Text
Keywords: anticancer; dose adjustment; renal dysfunction; hepatic dysfunction anticancer; dose adjustment; renal dysfunction; hepatic dysfunction
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Hendrayana, T.; Wilmer, A.; Kurth, V.; Schmidt-Wolf, I.G.; Jaehde, U. Anticancer Dose Adjustment for Patients with Renal and Hepatic Dysfunction: From Scientific Evidence to Clinical Application. Sci. Pharm. 2017, 85, 8.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Sci. Pharm. EISSN 2218-0532 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top